A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 1004-1011

  Cheng, Mindy M ^a   Goulart, Bernardo ^a,b   Veenstra, David L ^a   Blough, David K ^a   Devine, Emily Beth ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

B cell; Chronic; Leukemia; Lymphocytic; Meta analysis

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; PENTOSTATIN; RITUXIMAB;

CANCER GROWTH; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE ESCALATION; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIMULATION; SYSTEMATIC REVIEW;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIDARABINE;

EID: 84867141335     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.006     Document Type: Review

References (26)

1. Pinilla-Ibarz J., McQuary A. Chronic lymphocytic leukemia: putting new treatment options into perspective. Cancer Control 2010, 17:4-15.
2. Abbott B.L. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006, 11:21-30.
3. Steurer M., Pall G., Richards S., Schwarzer G., Bohlius J., Greil R., et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev 2006, 32:377-389.
4. Rai KR, Keating MJ. Initial treatment of chronic lymphocytic leukemia. UpToDate online 18.3, updated october 1, 2010.
5. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
6. Jansen J.P., Crawford B., Bergman G., Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008, 11:956-964.
7. Sutton A., Ades A.E., Cooper N., Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008, 26:753-767.
8. Ouwens M.J.N.M., Philips Z., Jansen J.P. Network meta-analysis of parametric survival curves. Res Syn Meth 2011, 1:258-271.
9. Jansen J.P. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol 2011, 11:61.
10. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
11. Lunn D.J., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modeling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
12. Ntzoufras I. Bayesian modeling using WinBUGS 2009, John Wiley & Sons, Inc., New Jersey.
13. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
14. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
15. Eichhorst B.F., Busch R., Stilgenbauer S., et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382-3391.
16. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
17. Catovsky D., Richards S., Matutes E., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007, 370:230-239.
18. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomize, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
19. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885-891.
20. Gentile M., Vigna E., Mazzone C., et al. Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Manage Res 2010, 2:71-81.
21. O'Brien S. Survival advantage in CLL with frontline FCR therapy. Curr Hematol Malig Rep 2011, 6:3-4.
22. Schenker N., Gentleman J.F. On judging the significance of differences by examining the overlap between confidence intervals. Am Stat 2001, 55:182-186.
23. Kay N.E., Shanafelt T.D. Prognostic factors in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2007, 2:49-55.
24. Main C., Pitt M., Moxham T., Stein K. The clinical and cost-effectiveness of rituximab for the 1st line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Health Technol Assess 2010, 14(Suppl. 2):27-32.
25. Song F., Altman D.G., Glenny A.M., Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472-476.
26. Higgins J.P.T., Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996, 15:2733-2749.